Abstract
The development of safe and effective antigen-specific therapies is needed to treat patients with autoimmune diseases. These therapies must allow for the specific tolerization of self-reactive immune cells without altering host immunity to infectious insults. Experimental models and clinical trials for the treatment of autoimmune disease have identified putative mechanisms by which antigen-specific therapies induce tolerance. Although advances have been made in the development of efficient antigen-specific therapies, translating these therapies from bench to bedside has remained difficult. Here, we discuss the recent advances in our understanding of antigen-specific therapies for the treatment of autoimmune diseases.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 665-677 |
| Number of pages | 13 |
| Journal | Nature Reviews Immunology |
| Volume | 7 |
| Issue number | 9 |
| DOIs | |
| State | Published - Sep 2007 |
Funding
Work in the Miller laboratory is supported by National Institutes of Health, USA, Grants P01 NS-030871, R01 NS-026543, R01 NS-030871; R01 NS-040460, R01 NS-048411; National Multiple Sclerosis Society Grants RG-3489, RG-3546, RG-3793, RG-3965; and a grant from the Myelin Repair Foundation.
ASJC Scopus subject areas
- Immunology and Allergy
- Immunology
